In breast and ovarian cancer cell lines, high SYCP2 expression correlated with resistance to Cisplatin, a DNA crosslinking agent, and Camptothecin 11 (CPT11, irinotecan), an inhibitor of TOP1 (Fig. 1G). This evidence concerns the gene TOP1 and ovarian cancer.